Radiotherapy in Ovarian Clear Cell Cancer

Mary McCormack - NCRI
GCIG Chicago 2017
ROCC Trial Design

Women with OCCC
Stage Ic2/3-II

3-weekly carboplatin (AUC 5-6) and paclitaxel (175 mg/m2) chemotherapy X 6 cycles

3-weekly carboplatin (AUC 5-6) and paclitaxel (175 mg/m2) chemotherapy X 3 cycles
Pelvic irradiation (45Gy in 25 fractions over 5 weeks)
ROCC Trial Design

• Median DFS for control arm of 5 years
• Aim to detect an improvement to 8 years
• HR = 0.625
• Power = 80%
• Two sided 5% significance level
• N = ~350
• 5 years of accrual and 3 years of follow-up
ROCC Current Status

- Joint Collaboration with Anna Tinker and Canadian colleagues
- CR UK Application Dec 2016 - Rejected
- Outline Application submitted to NIHR Health Technology Assessment Programme (HTA) on 5th April
- If invited for Full Application – committee review/outcome Nov 2017
- Translational component to identify molecular markers – pending application